Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Ivana Vaněčková"'
Autor:
Michal Behuliak, Michal Bencze, Almos Boroš, Anna Vavřínová, Martin Vodička, Peter Ergang, Ivana Vaněčková, Josef Zicha
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 176, Iss , Pp 116796- (2024)
Spontaneously hypertensive rats (SHR) are characterized by sympathetic hyperactivity and insufficient parasympathetic activity, and their high blood pressure (BP) can be lowered by long-term inhibition of the renin-angiotensin system. The aim of our
Externí odkaz:
https://doaj.org/article/37710a7104f548408806e36e7deb2210
Autor:
Silvie Hojná, Hana Malínská, Martina Hüttl, Zdeňka Vaňourková, Irena Marková, Denisa Miklánková, Jaroslav Hrdlička, František Papoušek, Jan Neckář, Petr Kujal, Michal Behuliak, Hana Rauchová, Michaela Kadlecová, David Sedmera, Kristýna Neffeová, Eva Zábrodská, Veronika Olejníčková, Josef Zicha, Ivana Vaněčková
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 174, Iss , Pp 116520- (2024)
A combination of liver and heart dysfunction worsens the prognosis of human survival. The aim of this study was to investigate whether empagliflozin (a sodium-glucose transporter-2 inhibitor) has beneficial effects not only on cardiac and renal funct
Externí odkaz:
https://doaj.org/article/ce293d8af73640869fc6eca6e079b0bb
Autor:
Petr Kala, Zdenka Vaňourková, Petra Škaroupková, Elżbieta Kompanowska-Jezierska, Janusz Sadowski, Agnieszka Walkowska, Josef Veselka, Miloš Táborský, Hana Maxová, Ivana Vaněčková, Luděk Červenka
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 158, Iss , Pp 114157- (2023)
Background: Association of congestive heart failure (CHF) and chronic kidney disease (CKD) worsens the patient’s prognosis and results in poor survival rate. The aim of this study was to examine if addition of endothelin type A (ETA) receptor antag
Externí odkaz:
https://doaj.org/article/b3ea6aebadce4060b3f9f0e3eada1410
Autor:
Silvie Hojná, Hana Rauchová, Hana Malínská, Irena Marková, Martina Hüttl, František Papoušek, Michal Behuliak, Denisa Miklánková, Zdeňka Vaňourková, Jan Neckář, Michaela Kadlecová, Petr Kujal, Josef Zicha, Ivana Vaněčková
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 144, Iss , Pp 112246- (2021)
The new antidiabetic drugs, gliflozins, inhibit sodium-glucose transporter-2 in renal proximal tubules promoting glucose and sodium excretion. This leads not only to a significant improvement of glucose control but also to the reduction of blood pres
Externí odkaz:
https://doaj.org/article/e201a9068c7440d880c7984feaa998e8
Autor:
Věra Čertíková Chábová, Petr Kujal, Zdeňka Vaňourková, Petra Škaroupková, Janusz Sadowski, Elzbieta Kompanowska-Jezierska, Vladimír Tesař, Bruce Hammock, John Imig, Hana Maxová, Luděk Červenka, Ivana Vaněčková
Publikováno v:
Kidney & Blood Pressure Research, Vol 44, Iss 6, Pp 1493-1505 (2019)
Introduction: Previous studies in Ren-2 transgenic hypertensive rats (TGR) after 5/6 renal ablation (5/6 NX) have shown that besides pharmacological blockade of the renin-angiotensin system (RAS) also increasing kidney tissue epoxyeicosatrienoic acid
Externí odkaz:
https://doaj.org/article/e825f8319c354c929117bd918f0dbf1d
Autor:
Silvie Hojná, Zoe Kotsaridou, Zdeňka Vaňourková, Hana Rauchová, Michal Behuliak, Petr Kujal, Michaela Kadlecová, Josef Zicha, Ivana Vaněčková
Publikováno v:
Biomedicines, Vol 10, Iss 10, p 2509 (2022)
Gliflozins (sodium-glucose transporter-2 inhibitors) exhibited renoprotective effects not only in diabetic but also in non-diabetic patients with chronic kidney disease (CKD). Controversial results were reported in experimental non-diabetic models of
Externí odkaz:
https://doaj.org/article/c1aa47ac95cc44c1b6738ee49f9010da
Autor:
Hana Malínská, Martina Hüttl, Irena Marková, Denisa Miklánková, Silvie Hojná, František Papoušek, Jan Šilhavý, Petr Mlejnek, Josef Zicha, Jaroslav Hrdlička, Michal Pravenec, Ivana Vaněčková
Publikováno v:
Biomedicines, Vol 10, Iss 9, p 2066 (2022)
Gliflozins (inhibitors of sodium-glucose cotransporter 2) show many beneficial actions beyond their antidiabetic effects. The underlying mechanisms of these additional protective effects are still not well understood, especially under non-diabetic co
Externí odkaz:
https://doaj.org/article/a6a72131a5de4a8d9c3d0274808e4d0b
Autor:
Ivana Vaněčková, Silvie Hojná, Zdenka Vernerová, Michaela Kadlecová, Hana Rauchová, Elzbieta Kompanowska-Jezierska, Zdeňka Vaňourková, Luděk Červenka, Josef Zicha
Publikováno v:
Frontiers in Physiology, Vol 10 (2019)
ObjectiveOur previous study in heterozygous Ren-2 transgenic rats (TGR) demonstrated that long-term treatment with endothelin receptor A (ETA) blocker atrasentan added to the renin-angiotensin system (RAS) blockade had renoprotective effects in a mod
Externí odkaz:
https://doaj.org/article/8daa08cb54f64a98ac0962f6e60ea410
Autor:
Lenka Sedláková, Věra Čertíková Chábová, Šárka Doleželová, Petra Škaroupková, Libor Kopkan, Zuzana Husková, Lenka Červenková, Soňa Kikerlová, Ivana Vaněčková, Janusz Sadowski, Elzbieta Kompanowska-Jezierska, Petr Kujal, Herbert J. Kramer, Luděk Červenka
Publikováno v:
Clinical and Experimental Hypertension, Vol 39, Iss 2, Pp 183-195 (2017)
Background: Early addition of endothelin (ET) type A (ETA) receptor blockade to complex renin–angiotensin system (RAS) blockade has previously been shown to provide better renoprotection against progression of chronic kidney disease (CKD) in Ren-2
Externí odkaz:
https://doaj.org/article/069801b85c634eb1ad2d34b86397326b
Autor:
Lenka Řezáčová, Silvie Hojná, Libor Kopkan, Hana Rauchová, Michaela Kadlecová, Josef Zicha, Ivana Vaněčková
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 116, Iss , Pp 108996- (2019)
Our previous studies demonstrated that chronic systemic blockade of renin-angiotensin system (RAS) lowered blood pressure (BP) of Ren-2 transgenic rats (TGR) by the attenuation of both angiotensin II-dependent and sympathetic vasoconstriction. Since
Externí odkaz:
https://doaj.org/article/c74b0e384337412ab98fb29865854402